89bio Inc. (ETNB) PT Lowered to $12 at RBC Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/10/2026
Go back to 89bio Inc. (ETNB) PT Lowered to $12 at RBC Capital
August 5, 2024 5:38 PM EDT
89bio, Inc. (NASDAQ: ETNB) reported Q2 EPS of ($0.48), $0.08 better than the analyst estimate of ($0.56).
For earnings history and earnings-related data on 89bio, Inc. (ETNB) click here.
...
More
August 5, 2024 8:04 AM EDT
89bio, Inc. (Nasdaq: ETNB) today announced the appointment of Dr. Charles McWherter to its Board of Directors, effective July 30, 2024. Dr. McWherter most recently served as Chief Scientific Officer and President of Research and Development of CymaBay Therapeutics until it was acquired by Gilead Sciences in March 2024.
We are thrilled to welcome Charles, an esteemed industry leader, to our Board of Directors, said Rohan Palekar, CEO of 89bio. His expertise in drug development and profound knowledge of liver inflammation and fibrosis will be highly valuable as we advance our Phase 3 trials for non-cirrhotic and... More
